US 11,806,369 B2
Exosomes and miRNA to treat glaucoma
Stanislav Ivanovich Tomarev, Kensington, MD (US); and Benjamin Frank John Martin Mead, Wales (GB)
Assigned to THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 7, 2021, as Appl. No. 17/341,057.
Application 17/341,057 is a division of application No. 16/257,026, filed on Jan. 24, 2019.
Claims priority of provisional application 62/622,032, filed on Jan. 25, 2018.
Prior Publication US 2021/0292758 A1, Sep. 23, 2021
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 35/28 (2015.01); A61P 27/10 (2006.01); C12N 5/0775 (2010.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01); A61K 31/5575 (2006.01); A61K 45/06 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/5575 (2013.01); A61P 27/10 (2018.01); C12N 5/0663 (2013.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01)] 15 Claims
 
1. A method of treating a subject with glaucoma, comprising:
selecting a subject with glaucoma, and
locally administering to an eye of the subject a therapeutically effective amount of an adenoviral associated virus (AAV) vector comprises at least three of a nucleic acid molecule encoding hsa-miR-17, a nucleic acid molecule encoding hsa-miR-26a-1, a nucleic acid molecule encoding hsa-miR-30c-2, a nucleic acid molecule encoding hsa-miR-92a-1, a nucleic acid molecule encoding rno-miR-292, and a nucleic acid molecule encoding hsa-miR-182,
thereby treating the glaucoma in the subject.